David Bajor, MD

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, David Bajor, MD sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).

2 total trials none currently recruiting 2 completed early-phase tilt upper half by trial count

David Bajor, MD: 2 sponsored US clinical trials, none currently recruiting.

David Bajor, MD sponsors 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 2 completed. 0 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Colon Cancer, with 1 trials.

Mid-pack sponsor footprint

David Bajor, MD is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Indexed trials (enrollment closed)

2 total, page 1 of 1

COMPLETED Phase 1

CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer

NCT03699319
COMPLETED Phase 1

CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer

NCT02861300

Phase Distribution

PhaseTrial count
Phase 1 2

Therapeutic Areas

Colon Cancer 1
Rectal Cancer 1
Colorectal Cancer 1
Solid Tumor 1

How the David Bajor, MD early-phase archive is shaped

2 indexed studies, none listed as recruiting (0% open); 2 completed (100%).

Phase mix: 0 late (III/IV) vs 2 early (I/II) (early-phase heavy).

Top condition: Colon Cancer (1 trial), 3 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

David Bajor, MD: archived-pipeline peers nationwide

Peers matched on 2 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

David Bajor, MD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%20%40%60% Total trials Recruiting share David Bajor, MD1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO Health10xBio22nd Century Group23andMe3-C Institute for Social Development
David Bajor, MD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

David Bajor, MD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 2 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this David Bajor, MD page

2 registered trials is a research-attention snapshot, not an endorsement of David Bajor, MD or any single study.

  • None of David Bajor, MD's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Colon Cancer is the condition David Bajor, MD studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Colon Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. David Bajor, MD pipeline card: 2 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.